Mucosan (Ambroxol Hydrochloride)

• Ambroxol Hydrochloride acts as a mucolytic and expectorant, facilitating the clearance of bronchial secretions in respiratory conditions.
• Acute bronchitis: loosens thick mucus to improve expectoration.
• Chronic bronchitis: reduces sputum viscosity for easier clearance.
• Chronic obstructive pulmonary disease (COPD): assists in managing productive cough by thinning secretions.
• Cough with thick or viscous sputum: enhances mucus transport and cough effectiveness.

• Ambroxol stimulates surfactant production by type II pneumocytes, decreases mucus viscosity and elasticity, and enhances ciliary activity in the respiratory epithelium. These actions collectively promote the mobilization and clearance of bronchial secretions, improving airway patency and facilitating expectoration.

Ambroxol is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea or upset stomach.
• Taste disturbances, often described as a bitter or salty taste.
• Diarrhoea or loose stools.
• Abdominal discomfort or cramping.
• Skin rash or mild itching.
• Headache.

Serious or Rare Side Effects

• Allergic reactions such as urticaria, angioedema or anaphylaxis.
• Severe skin reactions including Stevens‑Johnson syndrome.
• Eosinophilic pneumonia.
• Hepatic dysfunction presenting as jaundice or elevated liver enzymes.
• Acute bronchospasm in susceptible individuals.

• When using Ambroxol, consider the following safety measures.
• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: unknown excretion in milk; weigh benefits against possible infant exposure.
• Renal impairment: monitor renal function and adjust use if necessary.
• Asthma or reactive airway disease: observe for possible bronchospasm.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and direct sunlight.

Ambroxol may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid)

• Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase ambroxol plasma levels.
• Use with antitussive agents containing codeine may blunt the mucolytic effect and increase sedation risk.

Moderate Interactions (Monitor Closely)

• Concurrent use of other mucolytics (e.g., N‑acetylcysteine) may heighten gastrointestinal irritation.
• Combination with bronchodilators may enhance cough reflex; monitor patient response.
• NSAIDs may increase the risk of gastrointestinal upset when taken together.